CRISPR Therapeutics AG (CRSP) vs Erasca, Inc. (ERAS)

A side-by-side comparison of CRISPR Therapeutics AG and Erasca, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CRSP vs ERAS

growth of $100 · dividends reinvested · last 5y
CRSP -54.9% (-14.7%/yr)ERAS -15.5% (-3.3%/yr)ERAS compounded faster over this window
050100150Start $10020222023202420252026$45$84
CRSP ERAS

CRSP vs ERAS: by the numbers

  • •CRSP is the larger company ($5.24B vs $4.98B market cap).
  • •Both run net losses; ERAS's is the smaller (0.00% vs -3368.72% net margin).

Metrics side by side

Valuation

MetricCRSPERAS
P/S ratio391.65N/A
P/B ratio3.0013.77

Profitability

MetricCRSPERAS
Gross margin-6537.01%0.00%
Operating margin-16191.40%0.00%
Net margin-3368.72%0.00%
ROE-25.83%-79.37%
ROIC-21.12%-38.03%

Growth (annualized)

MetricCRSPERAS
Revenue CAGR (5Y)37.32%N/A
Total return CAGR (5Y)-10.97%-8.34%

Frequently asked

How have CRSP and ERAS total returns compared?
Over the past 5 years, CRSP delivered -10.97% and ERAS delivered -8.34% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.